Our CEO, David Harrell, once again turned heads—hat and all—as he introduced Helixomer’s RNA origami (RNAO) platform to a crowd of innovators and investors. With over 150 paused aptamer programs in clinical trials, there’s an urgent need for a smarter, stronger solution. Helixomer is that solution.

We’re building programmable RNA therapeutics that overcome the pitfalls of the past—poor therapeutic body availability time, lowered efficacy in vivo, immunogenic side effects, poor stability, and short half-life—unlocking new possibilities in precision medicine.

💡 Investors, partners, and pioneers: if you’re looking for the next generation of therapeutic platforms, we’re ready to talk.

👀 Keep your eyes on our website (helixomer.com) and LinkedIn—you’ll be the first to know where David and his cowboy hat show up next.

hashtag#Seed2Table hashtag#Helixomer hashtag#RNAOrigami hashtag#CowboyHatCEO hashtag#BiotechInnovation hashtag#PrecisionMedicine hashtag#AptamersReimagined hashtag#BiotechInvesting hashtag#NextGenTherapeutics